Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of NBI-98854 in Healthy Subjects

Inclusion Criteria: * Healthy male or female volunteer, 18 to 40 years of age. * Subjects of childbearing potential must agree to use hormonal or two forms of nonhormonal birth control during the study. * Female subjects must not be pregnant, given birth within 1 year of study start, or breastfeeding. * Be in good general health and expected to complete the clinical study as designed. * Have a body mass index (BMI) of 18 to 30 kg/m2 (both inclusive). Exclusion Criteria: * Have an active clinically significant unstable medical condition within 1 month (30 days) prior to screening. * Have a history of substance dependence or substance (drug) or alcohol abuse within the 3 months before study start. * Report more than two alcoholic beverages daily or more than 14 alcoholic beverages weekly withing 7 days of study start. * Report use of tobacco and/or nicotine-containing products within 3 months of study start. * Have a known history of neuroleptic malignant syndrome. * Have a significant risk of suicidal or violent behavior. * Have a positive human immunodeficiency virus antibody, (HIV-Ab), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibody result at screening or have a history of positive result. * Have received an investigational drug within 30 days before screening or plan to use an investigational drug (other than NBI-98854) during the study. * Have an allergy, hypersensitivity, or intolerance to tetrabenazine. * Had a blood loss greater than or equal to 500 mL or donated blood within 56 days of study start. * Have had previous exposure with NBI-98854.